Sugi Predict

Sugi Predict / Compounds / SCHEMBL1667926

SCHEMBL1667926

SCHEMBL1667926

FC(F)(F)c1cc(C2CC2)[nH]n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 3/20 0.47
▸ CCNA2 P20248 7/20 0.46
▸ CDK2 P24941 7/20 0.46
▸ CCNA1 P78396 7/20 0.46
▸ HCAR3 P49019 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAP4K4 O95819 1/20 0.42
▸ CRHBP P24387 1/20 0.40
▸ CRHR2 Q13324 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ MKNK1 Q9BUB5 2/20 0.39
▸ MKNK2 Q9HBH9 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16827884 0.87 KMT2A (0.55) CCNA2CDK2CCNA1MEN1POLB
SCHEMBL31625363 0.85 MEN1 (0.37) HCAR2CCNA2CDK2CCNA1HCAR3
SCHEMBL24759495 0.79 HCAR2 (0.47) HCAR2CCNA2CDK2CCNA1HCAR3
SCHEMBL21450656 0.76 CCNA2 (0.42) HCAR2CCNA2CDK2CCNA1HCAR3
SCHEMBL17688929 0.75 HCAR2 (0.49) HCAR2CCNA2CDK2CCNA1HCAR3
SCHEMBL24936178 0.75 HCAR2 (0.45) HCAR2CCNA2CDK2CCNA1HCAR3
Hydrochloric Acid SCHEMBL3502428 0.74 HCAR2 (0.40) HCAR2CCNA2CDK2CCNA1HCAR3
SCHEMBL22535481 0.72 MKNK1 (0.49) HCAR2HCAR3MEN1POLBKMT2A
SCHEMBL22327725 0.71 DAO (0.44) HCAR2CCNA2CDK2CCNA1HCAR3
SCHEMBL15375205 0.70 CA2 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025129135-A2 COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-06-19 — — WO disclosed
WO-2024146541-A1 MACROCYCLIC COMPOUNDS AS USP1 INHIBITORS GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2024-07-11 — — WO disclosed
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 — — US disclosed
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 — — US disclosed
US-20220370451-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2022-11-24 — — US disclosed
EP-3954679-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS Gilead Sciences, Inc. (US) 2022-02-16 — — EP disclosed
EP-3409667-B1 AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS GILEAD SCIENCES INC (US) 2021-07-21 — — EP disclosed
US-11034668-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2021-06-15 — — US disclosed
US-11034668-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2021-06-15 — — US disclosed
US-10668051-B2 Modulators of calcium release-activated calcium channel RHIZEN PHARMACEUTICALS SA (CH) 2020-06-02 — — US disclosed
US-20100240618-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2010-09-23 — — US disclosed
US-7589199-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2009-09-15 — — US disclosed
US-7589199-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2009-09-15 — — US disclosed
US-7589199-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2009-09-15 — — US disclosed
EP-1691810-A4 SUBSTITUTED PIPERAZINES CHEMOCENTRYX INC (US) 2009-07-01 — — EP disclosed
EP-1691810-A1 SUBSTITUTED PIPERAZINES ChemoCentryx Inc (US) 2006-08-23 — — EP disclosed
US-20060106218-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2006-05-18 — — US disclosed
US-20050256130-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2005-11-17 — — US disclosed
WO-2005056015-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2005-06-23 — — WO disclosed
US-20040162282-A1 Substituted piperazines CHEMOCENTRYX, INC. 2004-08-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10668051-B2 Modulators of calcium release-activated calcium channel ORAI1, CACNB2, CACNB1 HCAR2 258/4885CCNA2 3607/4885CDK2 2859/4885
US-20220370451-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, SAMHD1, POLR2H HCAR2 4611/4885CCNA2 1175/4885CDK2 133/4885
US-20060106218-A1 Substituted piperazines CCR1, CCR3, CCRL2 HCAR2 34/4885CCNA2 3473/4885CDK2 1388/4885
US-20050256130-A1 Substituted piperazines CCR1, CCR3, CCRL2 HCAR2 34/4885CCNA2 3473/4885CDK2 1388/4885
US-11034668-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN HCAR2 3961/4885CCNA2 3363/4885CDK2 2664/4885
US-20040162282-A1 Substituted piperazines CCR1, CCR3, CCRL2 HCAR2 31/4885CCNA2 3808/4885CDK2 1611/4885
US-20100240618-A1 SUBSTITUTED PIPERAZINES CCR1, CCR3, CCRL2 HCAR2 34/4885CCNA2 3473/4885CDK2 1388/4885
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN HCAR2 3961/4885CCNA2 3363/4885CDK2 2664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.